Clene (CLNN)
(Delayed Data from NSDQ)
$5.00 USD
-0.19 (-3.66%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.96 -0.04 (-0.80%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLNN 5.00 -0.19(-3.66%)
Will CLNN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLNN
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Other News for CLNN
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Clene’s CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy Recommendation
Buy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene’s CNM-Au8
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
Clene announces it will meet in-person with FDA to discuss CNM-Au8